Azoury Saïd C, Johnson F Bradley, Levine Matthew, Veasey Stephanie, McAndrew Christine, Shaked Abraham, Lantieri Laurent, Kamoun Malek, Levin L Scott
Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Transpl Immunol. 2021 Apr;65:101377. doi: 10.1016/j.trim.2021.101377. Epub 2021 Feb 18.
Vascularized composite allografts may be more susceptible to rejection than other types of organ transplants, particularly in sensitized recipients. We describe a successful transatlantic bilateral hand transplant in a 40-year old woman who was highly sensitized to class II HLA antigens including HLA-DPB1 (UNet CPRA = 86%). Prior to transplantation, we selected an upper limb donor based on HLA class II matching and absence of donor specific antibodies, given evidence that class II mismatches are associated with acute cellular rejection in hand transplants. The patient was conditioned using five doses of thymoglobulin, and her immunosuppression included tacrolimus, rapamycin, mycophenolate, and prednisone. Post-transplant, the patient non-DSA anti-HLA antibody levels drastically increased, but only transiently and weak DSAs developed, which became undetectable by two months posttransplant. Following transplantation, periodic biopsies over 6 months indicated no evidence of rejection except for transient Banff grade 1 and one sample with grade 2 acute rejection. There was no evidence of rejection on her recent 1-year follow-up. The patient is currently healthy, has recovered protective sensibility, and is regaining excellent function. This case highlights the importance of pre-transplantation planning, donor selection/compatibility, and ethical considerations in the ultimate success of VCA.
血管化复合组织异体移植可能比其他类型的器官移植更容易发生排斥反应,尤其是在致敏受者中。我们描述了一例成功的跨大西洋双侧手移植手术,受者是一名40岁的女性,她对包括HLA-DPB1在内的II类HLA抗原高度致敏(UNet CPRA = 86%)。鉴于有证据表明II类错配与手移植中的急性细胞排斥反应相关,在移植前,我们根据II类HLA匹配和无供者特异性抗体选择了一名上肢供者。患者接受了五剂胸腺球蛋白预处理,其免疫抑制方案包括他克莫司、雷帕霉素、霉酚酸酯和泼尼松。移植后,患者的非供者特异性抗HLA抗体水平急剧上升,但仅短暂出现且产生的供者特异性抗体较弱,在移植后两个月时变得无法检测到。移植后,6个月内的定期活检显示除了短暂的班夫1级和一个样本出现2级急性排斥反应外,没有排斥反应的迹象。在她最近的1年随访中没有排斥反应的证据。患者目前健康,已恢复保护性感觉,并且正在恢复良好的功能。该病例突出了移植前规划、供者选择/相容性以及伦理考量在血管化复合组织异体移植最终成功中的重要性。